Business Context and Reporting Period
This filing is an Amendment No. 1 to a Form 6-K submitted by Scinai Immunotherapeutics Ltd., a foreign private issuer based in Jerusalem, Israel. The report covers the period ending June 30, 2024, and was filed in September 2024. The primary purpose of this amendment is to furnish unaudited interim condensed consolidated financial statements for the period ended June 30, 2024, which were inadvertently omitted from the original Form 6-K filed on August 15, 2024.
Key Financial Metrics
The filing text provided serves as a cover sheet and explanatory note. It references the inclusion of financial statements as Exhibit 99.2 but does not contain the actual numerical data for revenue, profit, cash flow, margins, debt, or liquidity. Consequently, no specific financial metrics can be extracted from this text alone.
Material Changes
The filing does not disclose specific operational or financial changes compared to prior periods. The only material change noted is the correction of the filing record to include the previously missing unaudited interim financial statements for the six months ended June 30, 2024.
Guidance, Outlook, and Risks
This specific document does not contain management commentary, forward-looking guidance, risk factors, or details on contingencies. It references a press release (Exhibit 99.1) dated August 15, 2024, which may contain such information, but the content of that press release is not included in the provided text.
Investor Verification Checklist
- Review Exhibit 99.2 (Unaudited Interim Condensed Consolidated Financial Statements) to obtain actual cash balance, burn rate, and operating loss figures for the period ended June 30, 2024.
- Examine Exhibit 99.1 (Press Release) for any updates on clinical trial progress, regulatory milestones, or capital raise activities.
- Verify the incorporation of this report into the company's active Registration Statements (Form S-8 and Form F-3) as noted in the filing.
- Confirm the company's current cash runway based on the newly provided financial statements to assess liquidity risks.